The suit alleges that Novo Nordisk created a "false impression" of reliable data supporting this projection, while downplaying concerns about dosage tolerability. Specifically, the lawsuit ...

Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product delivered favorable results. The new drug, amycretin, similar to the company's ...

"Novo Nordisk reports topline data from Phase Ib/IIa trial of weight loss therapy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this ...

Novo Nordisk recently reported data from a phase 1b/2a clinical trial for the subcutaneous formulation of amycretin. The study enrolled 125 overweight or obese patients, with some receiving ...

Investing.com -- Shares of pharmaceutical giant Eli Lilly (NYSE:LLY) edged down 1.2% in premarket trading following announcements from competitor Novo Nordisk ... of the new data, stating ...

Novo Nordisk (NVO) announced Friday that its popular ... at a higher dose of 7.2 mg in a late-stage trial. Citing topline data from its STEP-UP Phase 3b study, the Danish drugmaker said that ...

Profit and prosper with the best of expert advice - straight to your e-mail. Novo Nordisk has underperformed the broad market on the price charts over the past 12 months, down 17% vs the S&P 500's ...

Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product delivered favorable results. The new drug, amycretin, similar to the company's ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw back the declines of the past ...

and continue to collaborate with external partners to ensure robust systems and processes are in place," Novo Nordisk said "This has enabled us to resubmit all relevant historical data to ...

Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results ...